- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00081913
Stem Cell Study for Patients With Heart Disease
Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia
Study Overview
Status
Intervention / Treatment
Detailed Description
The goal of this study is to determine the safety of various doses of autologous (one's own) stem cells, delivered with a catheter into the regions of the heart with poor blood flow. Stem cells are primitive cells produced by bone marrow that can develop into blood cells or other types of cells. In addition to determining whether this new approach is safe, the diagnostic tests may offer preliminary insights into the usefulness of this approach for treating myocardial ischemia (the condition where areas in the heart are lacking enough oxygen and blood flow to keep the heart muscle working well).
This is a blinded, randomized study to compare a certain type of stem cell called CD34-positive versus a placebo agent (normal saline). You will have a 3:1 chance of receiving your CD34-positive stem cells versus the placebo agent (normal saline). You will not know whether you received the CD34-positive cells or the placebo agent (normal saline). If you are randomized to receive placebo (normal saline), you will undergo all of the pre-treatment phases of this study (including the stem cell mobilization phase and the apheresis procedure), but rather than receiving injections of CD34-positive cells, you will receive injections of the placebo agent (normal saline). There is some research evidence that suggests CD34-positive cells may help develop new blood vessels or improve blood flow when injected directly into the heart muscle.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Clinic
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02135
- Caritas St. Elizabeth's Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Minneapolis Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with functional class (CCS) III or IV angina.
- Subjects who have attempted "best" medical therapy without control of symptoms.
- All subjects must have a recent coronary angiogram (within the last 3 months).
- Clinical signs and symptoms of clinically significant ischemia on nuclear perfusion imaging.
- Subjects must be able to complete a minimum of 1 minute but no more than 6 minutes of the Standard Bruce Protocol.
- Subject experiences angina during the baseline exercise tolerance test.
- Subjects must either be no longer capable of reproduction or taking acceptable measures to prevent reproduction during the study.
- Normal renal function.
- Normal liver function.
- Normal blood count.
Angiographic Inclusions:
- Total occlusion of an epicardial coronary artery.
- Candidates at high risk for percutaneous coronary angioplasty of treatment zone(s) based upon clinical or anatomic considerations including but not limited to the following: diabetes, congestive heart failure (severe right heart failure, NYHA class III or IV), left main disease, pulmonary hypertension, severe proximal vessel tortuosity, severe bendpoint obstructions, diffuse disease (>2 cm in length), small vessel (<2 mm reference diameter), stenosis which are either diffuse (>2 cm in length) or distal, incessant restenosis lesions, unfavorable bifurcation stenosis, and degenerated or thrombosed saphenous vein grafts.
Exclusion Criteria:
- Predominant congestive heart failure symptoms.
- Patients who have been hospitalized with a primary diagnosis of CHF in the prior 6 months.
- Patients who have had diuretics added to their medical regimen or an increase in diuretic dosage for signs or symptoms of CHF in the past 6 months.
- Patients with a left ventricular ejection fraction of less than 25% as determined by transthoracic echocardiography.
- Patients with physical findings consistent with ongoing uncontrolled CHF.
- Myocardial infarction within 30 days of treatment.
- Successful coronary revascularization procedures within 3 months of study enrollment.
- Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.
- History of severe aortic stenosis or insufficiency; severe mitral stenosis; or severe mitral insufficiency.
- Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
- Subjects with PT, PTT or platelet counts greater than the upper limit of normal and those with a hematocrit <35%.
- Subjects with uncontrolled hypertension.
- Currently enrolled in another investigational device or drug trial (IDE or IND) that has not completed the required follow-up period.
- History of alcohol or drug abuse within 3 months of screening.
- Joint or peripheral vascular disease that severely limits treadmill walking.
- Chronic obstructive pulmonary disease that severely limits walking or FEV1.0<30% predicted.
- Subjects who are pregnant or lactating.
- Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study.
- Subjects who test positive for HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications.
- Subjects with a known hypersensitivity to E. coli-derived proteins.
- Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00165
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
Foundation IRCCS San Matteo HospitalFondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaboratorsWithdrawnST-elevation Myocardial InfarctionItaly
-
INTEGRIS Baptist Medical CenterCompletedST Elevated Myocardial InfarctionUnited States
Clinical Trials on Cell Therapy - Autologous CD34 Positive Cells
-
Foundation for Biomedical Research and InnovationInstitute of Biomedical Research and Innovation, Kobe, Hyogo, Japan; Kobe City... and other collaboratorsTerminatedMyocardial Infarction | Coronary Artery Disease | Chest Pain | Angina | Chronic Myocardial IschemiaJapan
-
Translational Research Center for Medical Innovation...Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan; Kobe City...CompletedIschemia | Ulcer | Peripheral Vascular Diseases | Gangrene | Leg PainJapan
-
Losordo, Douglas, M.D.TerminatedMyocardial Ischemia | Cardiovascular Disease | Congestive Heart FailureUnited States
-
Losordo, Douglas, M.D.Baxter Healthcare CorporationCompletedPeripheral Vascular Disease | Peripheral Artery Disease | Critical Limb IschemiaUnited States
-
The Emmes Company, LLCNational Eye Institute (NEI); University of California, DavisActive, not recruitingCentral Retinal Vein OcclusionUnited States
-
GenethonInstitute of Child Health; Great Ormond Street Hospital for Children NHS Foundation...Completed
-
GenethonHôpital Necker-Enfants MaladesCompleted
-
Great Ormond Street Hospital for Children NHS Foundation...Recruiting
-
University of California, DavisCures Within Reach; Retina SocietyActive, not recruitingRetinitis PigmentosaUnited States
-
Imperial College LondonCompletedType 1 Diabetes | Type 2 DiabetesUnited Kingdom